Skip to main content
Equibles
MDXG logo

MDXG · Mimedx Group, Inc.

Track MDXG — free

Use MDXG with AI

Ask our own analyst here, or connect this data to the AI you already use.

Ask ALVIS about MDXG

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

or use your own AI

The free Equibles MCP server lets any client query SEC filings, earnings calls, KPIs, holdings and prices directly — read-only, OAuth-secured, cited to the filing.

ChatGPT Claude Gemini
Server URL
https://mcp.equibles.com/mcp
All connection guides →
$4.27 +0.07 (+1.67%) At close · Aug 14
Customer concentration — top 10 customers 22% of revenue

10 customers — 22% of revenue (the year ended December 31, 2025)

“For the years ended December 31, 2025, 2024, and 2023, our top ten customers accounted for 22%, 20% and 20%, respectively, of our net sales”

Key customers — 1% of revenue (the year ended December 31, 2025)

“net sales to all U.S. government accounts comprised approximately 1%, 1% and 2%, respectively, of our net sales.”
View the 10-K filed Feb 25, 2026
Market Cap
$622.40M
Shares
145.76M

Mimedx Group, Inc. Earnings Call Transcripts

Every quarterly earnings call for Mimedx Group, Inc. (MDXG) — the full transcript with speaker labels, the audio replay, AI call highlights and a management-tone score, plus the matching 8-K earnings release and the quarter's 10-Q or 10-K. Investor days and conferences appear here too.

Revenue & result across quarters

Revenue Net income YoY up YoY down artefacts
▲7.3% $67.69M −$8.43M '22 Q3 22-11-02 ▲46.4% $74.38M −$414,000 '22 Q4 23-01-09 ▲21.7% $71.68M −$4.98M '23 Q1 23-05-02 ▲21.5% $81.26M $1.20M '23 Q2 23-08-01 ▲20.7% $81.71M $8.53M '23 Q3 23-10-30 ▲16.7% $86.83M $53.48M '23 Q4 24-02-28 ▲18.2% $84.71M $9.26M '24 Q1 24-04-30 ▲7.3% $87.21M $17.62M '24 Q2 24-07-31 ▲2.9% $84.06M $8.10M '24 Q3 24-10-30 ▲7% $92.91M $7.44M '24 Q4 25-02-26 ▲4.1% $88.20M $7.02M '25 Q1 25-04-30 ▲13.1% $98.61M $9.62M '25 Q2 25-07-30 ▲35.3% $113.72M $16.75M '25 Q3 25-10-29 ▲27.1% $118.09M $15.19M '25 Q4 26-02-25 ▼33.1% $58.99M −$10.86M '26 Q1 26-04-29 LATEST ▼34.7% $64.36M −$14.84M '26 Q2 26-07-29
Earnings call
FY26 · Q2
2026-07-29
MIMEDX Second Quarter 2026 Operating and Financial Results Conference Call
Confident tone Profitability and cost actions Wound care reimbursement headwinds Product launches and 510(k) submissions
Revenue
$64.36M
▼ 34.7% YoY
Diluted EPS
$-0.10
▼ 266.7% YoY
Gross margin
69.0%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY26 · Q1
2026-04-29
Mimedx Group, Inc. Q1 FY2026 Earnings Call
Cautious tone Wound care market disruption Surgical business growth Regulatory and reimbursement issues
Revenue
$58.99M
▼ 33.1% YoY
Diluted EPS
$-0.07
▼ 240% YoY
Gross margin
70.6%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q4
2026-02-25
Mimedx Group, Inc. Q4 FY2025 Earnings Call
Positive tone Surgical business growth and momentum Clinical research and evidence generation Financial results and cash position
Revenue
$118.09M*
▲ 27.1% YoY
Gross margin
83.9%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY25 · Q3
2025-10-29
Mimedx Group, Inc. Q3 FY2025 Earnings Call
Confident tone Quarterly financial performance Product portfolio expansion Medicare LCD / reimbursement reform
Revenue
$113.72M
▲ 35.3% YoY
Diluted EPS
$0.11
▲ 120% YoY
Gross margin
83.5%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q2
2025-07-30
Mimedx Group, Inc. Q2 FY2025 Earnings Call
Confident tone Medicare reimbursement reform Product portfolio expansion LCDs and clinical evidence requirements
Revenue
$98.61M
▲ 13.1% YoY
Diluted EPS
$0.06
▼ 50% YoY
Gross margin
81.1%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q1
2025-04-30
Mimedx Group, Inc. Q1 FY2025 Earnings Call
Positive tone Medicare LCD and reimbursement disruption Financial performance and cash position Surgical business growth
Revenue
$88.20M
▲ 4.1% YoY
Diluted EPS
$0.05
▼ 16.7% YoY
Gross margin
81.2%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q4
2025-02-26
Mimedx Group, Inc. Q4 FY2024 Earnings Call
Confident tone Product portfolio innovation and launches Revenue growth and financial performance Regulatory and legal matters
Revenue
$92.91M*
▲ 7% YoY
Gross margin
81.8%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY24 · Q3
2024-10-30
Mimedx Group, Inc. Q3 FY2024 Earnings Call
Confident tone HELIOGEN launch progress Product portfolio expansion Reimbursement fraud / Medicare headwinds
Revenue
$84.06M
▲ 2.9% YoY
Diluted EPS
$0.05
▼ 16.7% YoY
Gross margin
81.8%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q2
2024-07-31
Mimedx Group, Inc. Q2 FY2024 Earnings Call
Positive tone Top-line growth and quarterly financials HELIOGEN xenograft launch and opportunity Product portfolio innovation (AMNIOEFFECT, EPIEFFECT)
Revenue
$87.21M
▲ 7.3% YoY
Diluted EPS
$0.12
▲ 1100% YoY
Gross margin
83.0%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q1
2024-04-30
Mimedx Group, Inc. Q1 FY2024 Earnings Call
Confident tone Product portfolio expansion and innovation Wound & Surgical market growth and new launches Revenue growth and Q1 financial performance
Revenue
$84.71M
▲ 18.2% YoY
Diluted EPS
$0.06
Gross margin
84.7%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY23 · Q4
2024-02-28
Mimedx Group, Inc. Q4 FY2023 Earnings Call
Confident tone Financial Performance & Growth EPIEFFECT Product Launch Balance Sheet & Cash Generation
Revenue
$86.83M*
▲ 16.7% YoY
Gross margin
84.1%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY23 · Q3
2023-10-30
Mimedx Group, Inc. Q3 FY2023 Earnings Call
Revenue
$81.71M
▲ 20.7% YoY
Diluted EPS
$0.06
Gross margin
81.9%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY23 · Q2
2023-08-01
Mimedx Group, Inc. Q2 FY2023 Earnings Call
Revenue
$81.26M
▲ 21.5% YoY
Diluted EPS
$0.01
Gross margin
83.3%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY23 · Q1
2023-05-02
Mimedx Group, Inc. Q1 FY2023 Earnings Call
Revenue
$71.68M
▲ 21.7% YoY
Diluted EPS
$-0.06
Gross margin
82.7%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY22 · Q4
2023-01-09
Mimedx Group, Inc. Q4 FY2022 Earnings Call
Revenue
$74.38M*
▲ 46.4% YoY
Gross margin
80.7%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY22 · Q3
2022-11-02
Mimedx Group, Inc. Q3 FY2022 Earnings Call
Revenue
$67.69M
▲ 7.3% YoY
Diluted EPS
$-0.09
Gross margin
82.0%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY22 · Q2
2022-08-02
Mimedx Group, Inc. Q2 FY2022 Earnings Call
Revenue
$66.88M
▼ 1.9% YoY
Diluted EPS
$-0.11
Gross margin
82.3%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY22 · Q1
2022-05-03
Mimedx Group, Inc. Q1 FY2022 Earnings Call
Revenue
$58.89M
▼ 1.8% YoY
Diluted EPS
$-0.11
Gross margin
83.1%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY21 · Q4
2022-01-10
Mimedx Group, Inc. Q4 FY2021 Earnings Call
Revenue
$50.81M*
▼ 25.9% YoY
Gross margin
86.0%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY21 · Q3
2021-11-02
Mimedx Group, Inc. Q3 FY2021 Earnings Call
Revenue
$63.07M
▼ 1.9% YoY
Diluted EPS
$-0.04
Gross margin
83.9%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY21 · Q2
2021-08-03
Mimedx Group, Inc. Q2 FY2021 Earnings Call
Revenue
$68.17M
▲ 27.1% YoY
Diluted EPS
$-0.03
Gross margin
81.3%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY21 · Q1
2021-04-28
Mimedx Group, Inc. Q1 FY2021 Earnings Call
Revenue
$59.97M
▼ 2.9% YoY
Diluted EPS
$-0.09
Gross margin
83.9%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY20 · Q4
2021-03-09
Mimedx Group, Inc. Q4 FY2020 Earnings Call
Revenue
$68.55M
▼ 10.3% YoY
Diluted EPS
$-0.17
Gross margin
84.2%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY20 · Q3
2020-11-04
Mimedx Group, Inc. Q3 FY2020 Earnings Call
Revenue
$64.30M
▼ 27.6% YoY
Diluted EPS
$-0.48
▼ 536.4% YoY
Gross margin
84.0%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY20 · Q2
2020-08-04
Mimedx Group, Inc. Q2 FY2020 Earnings Call
Revenue
$53.65M
▼ 20.4% YoY
Diluted EPS
$-0.08
Gross margin
84.7%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Showing 1–25 of 25 earnings calls
Key facts CIK 1376339 CUSIP 602496101 13F (30d) 213 filings 211 filers Visit website Investor relations

Report a Problem

Category
Description
Email (optional, for follow-up)